Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALPHADROL vs PERCORTEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective glucocorticoid receptor agonist with high potency, binding to the glucocorticoid receptor and modulating gene transcription, leading to anti-inflammatory and immunosuppressive effects.
Percorten (desoxycorticosterone pivalate) is a synthetic mineralocorticoid that binds to and activates the mineralocorticoid receptor (MR) in the renal distal tubule, leading to increased sodium reabsorption, increased potassium and hydrogen ion excretion, and water retention, thereby expanding extracellular fluid volume and increasing blood pressure.
Adjunctive therapy for short-term administration in severe allergic reactions,Management of inflammatory and autoimmune conditions,Off-label: Treatment of certain cancers (e.g., multiple myeloma, lymphoid malignancies)
Adjunctive therapy in adrenocortical insufficiency (Addison's disease) for mineralocorticoid replacement,Off-label: Treatment of orthostatic hypotension due to autonomic dysfunction
0.5 mg intravenously every 4 hours as needed; maximum 2 mg/day.
1-5 mg intramuscularly or subcutaneously daily with dose adjusted based on clinical response and electrolyte monitoring.
Terminal elimination half-life of 12-15 hours in healthy adults; prolonged in renal impairment (up to 30 hours) requiring dose adjustment.
Terminal elimination half-life is approximately 30-40 minutes. Clinically, the short half-life necessitates frequent dosing (e.g., every 6-12 hours) to maintain therapeutic effect in mineralocorticoid replacement.
Hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Primarily hepatic via reduction and conjugation; excreted in urine as metabolites. Desoxycorticosterone pivalate is a prodrug that is hydrolyzed to desoxycorticosterone, which is then metabolized.
Primarily renal excretion of unchanged drug (60-70%) and glucuronide conjugates (20-25%); biliary/fecal excretion accounts for 5-10%.
Renal (biliary/fecal negligible). Approximately 50-70% of a dose is excreted as metabolites in urine; <5% unchanged.
Highly protein bound (92-95%), primarily to albumin and alpha-1-acid glycoprotein.
Approximately 90-94% bound to albumin and corticosteroid-binding globulin (CBG).
0.8-1.2 L/kg; indicates extensive distribution into total body water with some tissue binding.
Vd approximately 0.5-0.8 L/kg. Clinical meaning: Distributes primarily into extracellular fluid; low Vd indicates limited tissue penetration.
Oral: 70-80% due to first-pass metabolism; intramuscular: 90-100%.
Oral: Approximately 50-70% (high first-pass metabolism). IM/SC: 100% (assumed).
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: administer 50% of dose; GFR <10 m L/min: avoid use due to risk of accumulation.
No specific GFR-based dose adjustments established; use with caution in renal impairment due to potential for fluid retention and hypertension.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
No specific Child-Pugh based dose adjustments; caution in severe hepatic impairment due to reduced metabolism and increased risk of adverse effects.
0.01 mg/kg intravenously every 4-6 hours; maximum 0.2 mg/kg/day.
0.1-0.3 mg/kg intramuscularly or subcutaneously daily, divided every 12-24 hours, with titration based on clinical response.
Initiate with 0.25 mg intravenously every 6 hours; titrate cautiously due to increased sensitivity and renal impairment.
Initiate at lower end of adult dose (1 mg daily) with careful monitoring for fluid overload and electrolyte disturbances due to age-related renal and cardiovascular changes.
None
None
Increased risk of infections due to immunosuppression,Adrenal suppression with prolonged use,Osteoporosis with long-term use,Exacerbation of diabetes mellitus,Psychiatric disturbances
May cause severe hypertension, edema, congestive heart failure, hypokalemia, or metabolic alkalosis. Monitor blood pressure, serum electrolytes, and body weight. Use with caution in patients with cardiac disease, renal impairment, or hepatic disease. Avoid excessive sodium intake.
Systemic fungal infections,Hypersensitivity to the drug or any component,Administration of live or live attenuated vaccines
Hypersensitivity to desoxycorticosterone or any component,Severe hypertension,Hyperkalemia,Edema or fluid overload states,Congestive heart failure,Severe renal impairment
Avoid grapefruit and grapefruit juice as they may increase drug levels. Take with food to reduce gastrointestinal irritation. Limit sodium intake to reduce fluid retention; consider potassium-rich foods.
Avoid high-potassium foods (e.g., bananas, oranges, salt substitutes) as Percorten increases potassium retention. Limit sodium intake to manage fluid balance.
ALPHADROL is contraindicated in pregnancy. First trimester exposure associated with increased risk of cleft palate, cardiac defects, and neural tube defects. Second and third trimester exposure can cause fetal growth restriction, oligohydramnios, and adrenal suppression. Risk category X.
Percorten (desoxycorticosterone pivalate) is a mineralocorticoid. Data in pregnant women are limited. In animal studies, corticosteroids have been shown to be teratogenic. Use during pregnancy only if clearly needed. First trimester: Possible increased risk of cleft palate and intrauterine growth restriction. Second and third trimesters: Potential for adrenal suppression in the fetus/newborn.
Excreted into breast milk; M/P ratio not reported. Potential for infant adrenal suppression and growth retardation. Breastfeeding not recommended during therapy and for at least 3 months after last dose.
Corticosteroids are excreted in breast milk in small amounts. Desoxycorticosterone pivalate specific data are lacking. M/P ratio not determined. At high maternal doses, monitor infant for signs of adrenal suppression. Use with caution.
Avoid use in pregnancy; no established dose adjustments; use lowest effective dose if unavoidable; increased clearance may require dose increase, but teratogenicity risk precludes use.
Pregnancy may increase clearance of corticosteroids, potentially requiring dose adjustments. However, specific pharmacokinetic data for Percorten are lacking. Use lowest effective dose and monitor clinical response and serum levels if available.
Monitor blood glucose closely in diabetic patients; may cause hyperglycemia. Administer with food to reduce GI upset. Taper dose over 1-2 weeks after prolonged use to avoid adrenal insufficiency. Avoid live vaccines during therapy.
Percorten (desoxycorticosterone pivalate) is a mineralocorticoid used for adrenal insufficiency. Monitor for hypertension, hypokalemia, and edema. Titrate dose based on blood pressure and serum potassium. Use with caution in heart failure or renal impairment.
Take with food or milk to prevent stomach upset.,Do not stop taking this medication suddenly without consulting your doctor.,Report any signs of infection (fever, sore throat) or unusual bleeding/bruising.,Avoid alcohol while on this medication.,Inform all healthcare providers that you are taking Alphadrol.
Take exactly as prescribed; do not miss doses.,Report rapid weight gain, swelling, or shortness of breath.,Avoid excessive salt intake; follow a low-sodium diet if advised.,Do not stop abruptly; taper under medical supervision.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALPHADROL vs PERCORTEN, answered by our medical review team.
ALPHADROL is a Mineralocorticoid that works by Selective glucocorticoid receptor agonist with high potency, binding to the glucocorticoid receptor and modulating gene transcription, leading to anti-inflammatory and immunosuppressive effects.. PERCORTEN is a Mineralocorticoid that works by Percorten (desoxycorticosterone pivalate) is a synthetic mineralocorticoid that binds to and activates the mineralocorticoid receptor (MR) in the renal distal tubule, leading to increased sodium reabsorption, increased potassium and hydrogen ion excretion, and water retention, thereby expanding extracellular fluid volume and increasing blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALPHADROL and PERCORTEN depend on the specific clinical indication. These are both Mineralocorticoid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALPHADROL is: 0.5 mg intravenously every 4 hours as needed; maximum 2 mg/day.. The standard adult dose of PERCORTEN is: 1-5 mg intramuscularly or subcutaneously daily with dose adjusted based on clinical response and electrolyte monitoring.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALPHADROL and PERCORTEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALPHADROL is classified as Category C. ALPHADROL is contraindicated in pregnancy. First trimester exposure associated with increased risk of cleft palate, cardiac defects, and neural tube defects. Second and third trime. PERCORTEN is classified as Category C. Percorten (desoxycorticosterone pivalate) is a mineralocorticoid. Data in pregnant women are limited. In animal studies, corticosteroids have been shown to be teratogenic. Use duri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.